Opexa Therapeutics will price a public offering of its common stock

Aegis helps in funding clinical development of Tcelna, Phase IIb study

By Devika Patel

Knoxville, Tenn., June 17 - Opexa Therapeutics, Inc. plans to price a public offering of common stock with a 30-day greenshoe option, according to a Form S-1 filed Monday with the Securities and Exchange Commission.

Aegis Capital Corp. is assisting.

Proceeds will be used for clinical development of Tcelna and the Phase IIb study in patients with secondary progressive multiple sclerosis, operations and general corporate purposes, including debt repayment.

The Woodlands, Texas-based Opexa develops and commercializes cell therapies to treat autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis and diabetes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.